Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China

Overview of attention for article published in Frontiers in Public Health, June 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Readers on

mendeley: 13 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 23,784 followers.

RT @FrontPubHealth: New Research: Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line The…

29 Jun 2022

Reply Repost Favourite

New Research: Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China: This study aimed to evaluate and compare… https://t.co/SUQVGiUdV3 #PublicHe

29 Jun 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.